002589.SZ SHZ
Realcan Pharmaceutical Group Co., Ltd.
1W: -8.9%
1M: +2.8%
3M: +26.2%
YTD: -2.7%
1Y: +5.5%
3Y: -2.7%
5Y: -26.0%
¥3.27 ($0.49)
+0.03 (+0.93%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$160M
+94.6% ▲
5Y CAGR: -40.2%
Capital Expenditures
$112M
+62.6% ▲
5Y CAGR: -34.6%
Free Cash Flow
$49M
+122.7% ▲
5Y CAGR: -46.9%
Dividends Paid
$199M
+1.5% ▲
Buybacks
$33M
-16.8% ▼
Net Change in Cash
$218M
+1533.8% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $625M | $382M | -$1.7B | $20M | $41M |
| Depreciation & Amort. | $338M | $364M | $317M | $220M | $199M |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$1.2B | -$789M | $137M | -$262M | -$215M |
| Other Non-Cash Items | $0 | $0 | $1.8B | $275M | $135M |
| Operating Cash Flow | $415M | $443M | $523M | $82M | $160M |
| — Investing Activities — | |||||
| Capital Expenditures | -$505M | -$461M | -$171M | -$298M | -$112M |
| Acquisitions (Net) | -$116M | $9M | $1.0B | $1.2B | $226M |
| Investment Purchases | -$410M | -$50M | -$273M | -$297M | -$84M |
| Investment Sales | $29M | $21M | $33M | $11M | $175M |
| Other Investing | $59M | -$103M | -$29M | $0 | -$1M |
| Investing Cash Flow | -$944M | -$584M | $593M | $580M | $204M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$201M | -$285M | $1.6B | $1.4B | -$248M |
| Stock Repurchased | -$8M | -$4M | -$30M | -$29M | -$33M |
| Dividends Paid | -$347M | -$316M | -$13M | -$202M | -$199M |
| Other Financing | $0 | $555M | -$3.0B | -$1.9B | $334M |
| Financing Cash Flow | -$1.1B | -$50M | -$1.5B | -$677M | -$146M |
| Net Change in Cash | -$1.6B | -$191M | -$349M | -$15M | $218M |
| Cash End of Period | $1.0B | $836M | $487M | $472M | $690M |
| Free Cash Flow | -$141M | -$18M | $352M | -$216M | $49M |